Loading…
ARS Pharmaceuticals, Inc. is projected to rise to $8.59 by 2027, a +8% move from its current price of $7.94. SPRY is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $7.65 | $7.93 | $8.23 | -0.07% |
| Jul 13 | $7.53 | $7.93 | $8.35 | -0.15% |
| Jul 14 | $7.44 | $7.92 | $8.44 | -0.22% |
| Jul 15 | $7.36 | $7.92 | $8.51 | -0.30% |
| Jul 16 | $7.29 | $7.91 | $8.58 | -0.37% |
| Jul 17 | $7.23 | $7.90 | $8.64 | -0.45% |
| Jul 18 | $7.17 | $7.90 | $8.70 | -0.52% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $7.17 | $7.90 | $8.70 | -0.52% |
| Week 2 | $6.86 | $7.86 | $9.00 | -1.04% |
| Week 3 | $6.61 | $7.82 | $9.24 | -1.56% |
| Week 4 | $6.41 | $7.78 | $9.43 | -2.07% |
| Week 5 | $6.24 | $7.74 | $9.60 | -2.58% |
| Week 6 | $6.08 | $7.69 | $9.74 | -3.09% |
| Week 7 | $5.93 | $7.65 | $9.88 | -3.59% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ARS Pharmaceuticals, Inc. is a biopharmaceutical company that develops and commercializes treatments for severe allergic reactions in the United States and internationally.
The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.
ARS Pharmaceuticals was founded in 2015 and is headquartered in San Diego, California.
ARS Pharmaceuticals, Inc. (SPRY) is a healthcare stock currently trading at $8.02. It has a market cap of $796.41M and is ranked 2711.
The forecast path for SPRY shows a neutral tone near the start of the horizon and a bullish tilt later, with year-by-year Avg and max values that imply upside potential through 2030 and beyond. Notably, the 2026 forecast carries a neutral stance with an avg of $8.02, and the trajectory brightens into the 2030s and 2040s with steadily higher avg prices and max levels.
The path from 2026 to 2050 includes a sequence of growing forecasts, including 2030 avg $13.97 and max $22.28 (ROI 74.2) and bullish sentiment, continuing through 2040 avg $27.78 and max $53.89 (ROI 246.4) and culminating in 2050 avg $64.60 and max $140.41 (ROI 705.4), all tagged as BULLISH from 2030 onward.
A major floor 22.8% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.8% away) — a key level to hold.
The nearest ceiling, 32.7% above — a clean break opens room to run.
A major ceiling 44.2% above — clearing it would confirm fresh momentum.
Key SPRY support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SPRY market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $8.09 | Sell | $8.07 | Sell |
| MA 10 | $8.21 | Sell | $8.31 | Sell |
| MA 20 | $8.96 | Sell | $8.59 | Sell |
| MA 50 | $8.71 | Sell | $8.71 | Sell |
| MA 100 | $8.60 | Sell | $8.91 | Sell |
| MA 200 | $9.28 | Sell | $9.63 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 41.67 | Neutral |
| Stoch RSI (14) | 6.99 | Buy |
| CCI (20) | -79.99 | Neutral |
| Williams %R (14) | -97.74 | Info |
| MACD (12,26,9) | -0.16 | Sell |
| ROC (12) | -22.76 | Sell |
| Bollinger %B (20,2) | 0.22 | Neutral |
| Stochastic %K (14) | 2.26 | Buy |
| TRIX (15) | -0.14 | Sell |
| Awesome (5,34) | -0.82 | Sell |
| Ultimate (7,14,28) | 43.67 | Neutral |
| Momentum (10) | -0.08 | Sell |
| Aroon Osc (25) | -40.00 | Sell |
| Hull MA (9) | 7.94 | Sell |
| ADX (14) | 16.50 | Neutral |
| ATR (14) | 0.33 | Info |
The 30-day technical picture is NEUTRAL with RSI14 at 40.
The stock sits around key moving averages, with a 50-day SMA of $8.69 and a 200-day SMA of $9.37. Support is at $7.17 and resistance at $10.54, framing a 30-day range of $6.15 to $10.45.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.17 | $7.94 | $9.50 | 0% | Neutral | |
| $6.62 | $8.59 | $11.90 | +8% | Neutral | |
| $6.69 | $9.01 | $13.09 | +14% | Neutral | |
| $6.47 | $9.00 | $13.55 | +13% | Neutral | |
| $8.87 | $12.71 | $19.74 | +60% | Bullish | |
| $9.94 | $14.62 | $23.31 | +84% | Bullish | |
| $9.83 | $14.82 | $24.19 | +87% | Bullish | |
| $10.35 | $15.97 | $26.64 | +101% | Bullish | |
| $9.59 | $15.14 | $25.75 | +91% | Bullish | |
| $10.24 | $16.51 | $28.59 | +108% | Bullish | |
| $14.54 | $25.93 | $48.39 | +227% | Bullish | |
| $25.50 | $54.47 | $113.21 | +586% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $7.17 | $7.94 | $9.46 | +0.00% |
| August 2026 | $6.27 | $7.47 | $9.19 | -5.92% |
| September 2026 | $6.17 | $7.42 | $9.26 | -0.70% |
| October 2026 | $6.27 | $7.60 | $9.60 | +2.51% |
| November 2026 | $6.12 | $7.47 | $9.53 | -1.76% |
| December 2026 | $6.01 | $7.38 | $9.50 | -1.21% |
Click any year to see its month-by-month SPRY forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, SPRY could reach as high as $9.50, with a base case around $7.94 and support toward $7.17 — roughly 0% from $7.94. A consolidation phase looks the most probable path here.
Expect SPRY to range from $6.62 to $11.90 through 2027. The $8.59 average target implies a +8% move from current prices. That is up +8% on the projected 2026 average. Price action looks broadly range-bound.
The SPRY price prediction for 2028 points to an average of $9.01 (low $6.69, high $13.09) — a potential gain of +14% on today's $7.94. A consolidation phase looks the most probable path here.
In 2029, SPRY is projected to trade between $6.47 and $13.55, averaging $9.00 — a potential gain of +13% from today's $7.94. That is 0% versus the projected 2028 average. Price action looks broadly range-bound.
ARS Pharmaceuticals, Inc.'s 2030 outlook centres on $12.71, within a $8.87 to $19.74 range. That is up +41% on the projected 2029 average. That marks a +60% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, SPRY could reach as high as $23.31, with a base case around $14.62 and support toward $9.94 — roughly +84% from $7.94. Momentum favours further upside here.
Expect SPRY to range from $9.83 to $24.19 through 2032. The $14.82 average target implies a +87% move from current prices. That is up +1% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The SPRY price prediction for 2033 points to an average of $15.97 (low $10.35, high $26.64) — a potential gain of +101% on today's $7.94. Momentum favours further upside here.
In 2034, SPRY is projected to trade between $9.59 and $25.75, averaging $15.14 — a potential gain of +91% from today's $7.94. That is -5% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
ARS Pharmaceuticals, Inc.'s 2035 outlook centres on $16.51, within a $10.24 to $28.59 range. That is up +9% on the projected 2034 average. That marks a +108% change versus current levels. Momentum favours further upside here.
By 2040, SPRY could reach as high as $48.39, with a base case around $25.93 and support toward $14.54 — roughly +227% from $7.94. Buyers look set to stay in control over this stretch.
Expect SPRY to range from $25.50 to $113.21 through 2050. The $54.47 average target implies a +586% move from current prices. That is up +110% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in SPRY today (≈ 125.944584 SPRY) could be worth
$6,859.93
+$5,859.93 (+586%) by 2050 · US Dollar
Based on the average projected SPRY price of $54.47 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SPRYwould be worth at today's price.
$1,000 invested in SPRY on Jul 10, 2025 (≈ 55.617354 SPRY) would be worth
$441.6
-$558.4 (-55.8%) today · 0.44× · US Dollar
Based on a SPRY entry price of $17.98 vs. today's $7.94.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $8.56 | $927.57 | -7.2% |
| 1 month ago | $9.26 | $857.45 | -14.3% |
| 3 months ago | $8.05 | $986.34 | -1.4% |
| 6 months ago | $11.38 | $697.72 | -30.2% |
| 1 year ago | $17.98 | $441.6 | -55.8% |
| All time (5.0y) ago | $30.93 | $256.71 | -74.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SPRY forecast.
Our base-case forecast reaches $16.00 around 2035.
Implied market cap at $16.00: $1.59B
Over the multi-year forecast, SPRY shifts from neutral in the near term to bullish in the longer horizon. By 2030 the avg forecast is $13.97 with a max of $22.28 and ROI of 74.2, with a BULLISH sentiment signal.
The forecast continues bullish into 2040, where the avg is $27.78 and the max is $53.89 with ROI 246.4, and reaches by 2050 an avg of $64.60 and a max of $140.41 with ROI 705.4.
These figures illustrate a substantial upside path from the 2026–2029 neutral phase into a long-run bullish trajectory, but they are estimates and not guarantees, reflecting potential variations in performance over time.
Tap a question to reveal the answer.
In 2030, the forecast shows min $9.49, avg $13.97, max $22.28, ROI 74.2; sentiment BULLISH.
Forecasts show neutral sentiment in the near term (2026–2029) and bullish sentiment from 2030 onward, with the avg price rising to $13.97 by 2030 and to $64.60 by 2050 (ROI 74.2 and 705.4 respectively).
Yes, the max forecast by 2050 is $140.41, indicating the potential to exceed $100 in the long run.
Current price is $8.02 and market cap is $796.41M.
The 30-day range is $6.15 to $10.45.
ARS Pharmaceuticals, Inc. Community Discussion
0Share your ARS Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.